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Available online 9 May 2016Introduction: Pulmonary arterial hypertension (PAH), deﬁned as a systolic pulmonary artery pressure above
35 mm Hg, is another vascular disease entity recently described in patients receiving hemodialysis. It is a
major problem due to its high prevalence and morbidity and mortality. Its pathophysiological mechanism is
just known and the strategies for its supported not yet deﬁned.
Aims: To determine the prevalence of PAH in our hemodialysis patients and its risk factors.
Methodology: Single center descriptive and analytical cross-sectional study, including 111 hemodialysis patients
who had beneﬁt from a trans-thoracic cardiac Doppler ultrasound during 2014. A value greater than or equal
to 35 mm Hg is considered PAH and classiﬁed as follows: mild PAH (35 50 mm Hg), moderate PAH
(50 70 mm Hg), and severe pulmonary hypertension (N70 mm Hg). Patients with a high probability of secondary
PAH, especially those with the following history: chronic obstructive pulmonary disease, pulmonary embolism,
were not included.
Results: The mean age was 44.3 ± 14.2 years. Among the 111 patients, 18 had pulmonary arterial pressure above
35 mm Hg corresponding to 16.22% of PAH prevalence. The average pressure was 45 mmHg. Of these 18 patients,
11.8% hadmild PAH, 3.4%moderate PAH and 0.8% severe PAH. The average hemodialysis duration was signiﬁcantly
associatedwith PAH (p=0.003); aswell as valvular calciﬁcation (p=0.000), mitral regurgitation (p=0.001) and
tricuspid regurgitation (p = 0.002).
Conclusion: Primary pulmonary hypertension is a major problem among our hemodialysis because of its high prev-
alence and its risk factors.
© 2016 Published by Elsevier Ireland Ltd. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).Keywords:
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Risk factors1. Introduction
Pulmonary arterial hypertension (PAH), pulmonary vascular dis-
ease, is deﬁned by the elevation of systolic pulmonary arterial pressure
above 35 mm Hg measured by cardiac Doppler ultrasound [1]. Besides
the classic cardiovascular conditions recognized as one cause ofmorbid-
ity and mortality in the hemodialysis patients [2], primary PAH whose
mechanisms are incompletely known, is another vascular disease entity
recently described in chronic kidney disease (CKD) particularly for pa-
tients undergoing hemodialysis. It corresponds to 5th subtype of
WSPH classiﬁcation (World Symposium of Pulmonary Hypertension)
established in 2008 in Dana Point [3] and updated in 2013 in Nice. [4]
Primary pulmonary hypertension is a major problem of hemodialysis
patients because of its high prevalence, sometimes reaching 68% [5–8],
and by its signiﬁcantmorbidity andmortality [9]. Its pathophysiological
mechanism is just known and the strategies for its taken care not yet de-
ﬁned [10–14]. Our study aims to determine the prevalence of PAH in our
hemodialysis patients and its risk factors.Kadou-Kaza).
is an open access article under the C1.1. Methodology
This was a single-center descriptive and analytical cross sectional
study, single-center, which included 111 patients aged 18 years and
over, undergoing hemodialysis formore than sixmonths in dialysis cen-
ter of Ibn Rochd University Hospital of Casablanca in Morocco, and who
had beneﬁted from a trans-thoracic cardiac Doppler ultrasound during
2014. The pulmonary arterial pressure was measured using the echo-
cardiography. A value greater than or equal to 35 mm Hg is considered
PAH and classiﬁed as follows:mild PAH (35–50mmHg), moderate PAH
(50–70 mm Hg), and severe pulmonary hypertension (N70 mm Hg)
[15]. Patients with a high probability of secondary PAH, especially
those with the following history: chronic obstructive pulmonary
disease, pulmonary embolism, congenital heart disease, acute heart
failure, moderate or severe valve disease, aortic valve disease ormoder-
ate mitral or severe, connectivity, and sleep apnea were not included.
Also patients with overload ﬂuid were not included in the study.
Sociodemographic, clinical, and laboratory data were obtained from
medical records. Verbal consent was obtained from patients. Data
were entered and analyzed using the Sphinx software. The comparison
of means was performed by the Student's t test or the nonparametricC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Table 2
Trans-thoracic cardiac Doppler ultrasound data (n = number of patients).
Data Patients (n = 111)
EF (Average ± SD), % 62,5 ± 10.5
PAP, n(%)
PAP ≤ 35 mm Hg 93(83.78)
PAP ˃ 35 mm Hg 18(16.22)
Valvular calciﬁcation, n(%) 17(15.32)
Mitral regurgitation, n(%) 45(40.54)
Tricuspid regurgitation, n(%) 46(41.44)
EF: ejection fraction; PAP: pulmonary arterial hypertension.
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test or Fisher's exact test. A value of p ˂ 0.05 was considered signiﬁcant.
Multivariate analysis was performed by logistic regression model.
2. Results
The average age of our patients was 44.3 ± 14.2 years (range
18–90 years) with a female predominance in 51.4%. The average dura-
tion of hemodialysis was 146 ± 80months (12 years). Chronic glomer-
ulonephritis predominated causal nephropathy (Table 1). Among the
111 patients, 18 had pulmonary arterial pressure above 35 mm Hg
corresponding to 16.22% of PAH prevalence. The average pressure was
45 mm Hg (Table 2). Of these 18 patients, 11.8% had mild PAH (35–
50 mm Hg), 3.4% moderate PAH (50–70 mm Hg), and 0.8% severe
PAH (˃70 mm Hg). In multivariate analysis of risk factors (Table 3), the
average duration of hemodialysis was signiﬁcantly associated with
PAH (p=0.003); aswell as valvular calciﬁcation (p=0.000),mitral re-
gurgitation (p = 0.001) and tricuspid regurgitation (p = 0.002).
3. Discussion
The primary PAH of patients receiving hemodialysis, is a recently de-
scribed disease [1]. Its incidence is still unknown. Its prevalence report-
ed in the literature comes from studies based as ours on the trans
thoracic cardiac ultrasound [12]. In our study, the prevalence of PAH es-
timated at 16.22%. If this prevalence is similar to that reported by Li et al.
in China which is 20% [16], it is signiﬁcantly less compared to that re-
ported in most other studies that are often between 30 and 68% [5–8].
This difference in prevalence between our study and those of the litera-
turewould be partly due to the inaccuracy of themethod of diagnosis of
PAH that is ultrasound because the result of it depends on the operator's
experience. However the prevalence of PAH in patients undergoing he-
modialysis, overall remains relatively high and this would be multifac-
torial. Indeed, hemodialysis patient combines many factors involved in
the pathophysiology of primary pulmonary hypertension [12]. These
factors include uremic toxins, chronic inﬂammation, endothelial dys-
function, and mineral bone disorders, malnutrition, the phenomena of
bioincompatibility [17]. The existence of chronic inﬂammation in the
uremic is well established [17]. Similarly the proliferation of monocytes
and proinﬂammatorymast cells, and T cell dysfunction has been report-
ed [18]. Increased oxidative stress with excessive production of vaso-
constrictive substances such as endothelin-1 and angiotensin II, and
the reduction of the synthesis of vasodilators such as nitric oxide
(NO), all lead to pulmonary endothelial dysfunction which leads to
PAH [19].
In our study, the hemodialysis duration was signiﬁcantly associated
with the occurrence of PAH conﬁrming the result of many other [20]
studies. This could be explained by the worsening of inﬂammatoryTable 1
Epidemiological data (n = number of patients).
Data Patients (n = 111)
Clinical data
Age (average ± SD), year 44.3 ± 14.2
Female sex, n(%) 57(51)
Hemodialysis data
Hemodialysis duration (average ± SD), month 146 ± 80
Causal nephropathy, n(%)
Diabetes 7(6.2)
Chronic glomerulonephritis 19(17.1)
Nephroangiosclerosis 6(5.4)
Unknown nephropathy 50(45.0)
Others 29(26.1)
SD: standard deviation.phenomena due to incompatibilities of dialysis membrane [20]. Also,
in our patients, valvular calciﬁcations were signiﬁcantly associated
with the occurrence of PAH;which is not the case of data in the literature.
Indeed valvular calciﬁcations were previously considered as a major
cause of cardiovascular disease [12] such as PAH in patients with CKD.
However, all the studies that tried to correlate valvular calciﬁcations
with PAH in patients with CKD failed [21]. In our study, themitral and tri-
cuspid regurgitationwere found to be signiﬁcantly associatedwith the oc-
currence of PAH.However there is no consensus to predict the occurrence
of PAH on the abnormalities of cardiac ultrasound in CKD [12]. In Fabio
et al.’s study in Italy [22] onlymitral regurgitationwas signiﬁcantly corre-
lated with PAH in dialysis patients. In the study of Yigla et al. [23], PAH
was signiﬁcantly correlated with valvular disease.
The limitation of our study initially is in its methodology. Indeed for
the diagnosis of PAH, right catheterization is the gold standard, so we
used the trans thoracic cardiac ultrasound which may under or overes-
timate the prevalence [12]. Another limitation of our study is that we
had not evaluated all aspects including the treatment of PAH patients
receiving hemodialysis.4. Conclusion
Primary pulmonary hypertension is not only a reality in our hemodi-
alysis patients, but also appears as amajor problem due to its high prev-
alence and its risk factors which are essentially cardiovascular such as
valvular abnormalities. Primary PAH constitute a signiﬁcant cause of
mortality in hemodialysis patients [9]. Hence early detection of these
risk factors is needed for adequate care, only way to prevent the onset
of PAH.Conﬂicts of interest
None.Table 3
Risk factors of pulmonary arterial hypertension in multivariate analysis.
Data Patients P value
PAP ≤ 35 mm Hg PAP ˃ 35 mm Hg
n = 93 n = 18
Age (average ± SD), year 44 ± 13 46 ± 16 0.710
Sex, %
Male 47.31 55.56 0.520
Female 52.69 44.44
Duration of hemodialysis, month 147 ± 83 142 ± 74 0.003
EF (average ± SD), % 64.5 ± 11.5 56.3 ± 9.4 0.840
Valvular calciﬁcation, % 11.83 33.33 0.000
Mitrale regurgitation, % 34.41 72.22 0.002
Tricuspid regurgitation, % 34.41 77.78 0.001
PTHi (average ± SD), pg/ml 533 ± 29 513 ± 34 0.470
Anemia (average ± SD), g/dl 10.1 ± 2.3 9.5 ± 3.5 0.522
Albuminemia (average ± SD), g/l 43.2 ± 5.1 42.3 ± 6.3 0.843
EF: ejection fraction; PAP: pulmonary arterial pressure; PTHi: parathormon.
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